DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Zeiser R, von Bubnoff N, Butler J. et al; REACH2 Trial Group.
Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease.
N Engl J Med 2020;
382 (19) 1800-1810
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.